Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of radiofrequency ablation followed by Durvalumab plus Tremelimumab in hepatocellular carcinoma
jRCTs041240049Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jun 2024; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs041240049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240049.